Why the study?
Is serum ANGPTL8 associated with subclinical atherosclerosis in patients with type 2 diabetes?
Population
Type 2 diabetic patients from the GDMD study
Design
Cross-sectional
Authors
Loading...
No immediate change to T2D atherosclerosis assessment; leaves open ANGPTL8 as biomarker pending prospective validation.
Is serum ANGPTL8 associated with subclinical atherosclerosis in patients with type 2 diabetes?
Serum ANGPTL8 may serve as a novel biomarker for subclinical atherosclerosis in patients with type 2 diabetes.
Zheng et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: